A single dose bioavailability study of 2 new formulations of HKI-272 (240 mg) [neratinib] compared with a reference capsule and an oral solution in healthy adult subjects.

Trial Profile

A single dose bioavailability study of 2 new formulations of HKI-272 (240 mg) [neratinib] compared with a reference capsule and an oral solution in healthy adult subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2012

At a glance

  • Drugs Neratinib (Primary)
  • Indications Breast cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 11 May 2012 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 12 Dec 2007 Status change from in progress to completed.
    • 11 Sep 2007 Status changed from initiated to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top